Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
39 hedge funds and large institutions have $37.3M invested in Merrimack Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 43 → 39 (-4)
26% less capital invested
Capital invested by funds: $50.5M → $37.3M (-$13.2M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
74% less call options, than puts
Call options by funds: $215K | Put options by funds: $839K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$689K |
| 2 |
BlackRock
New York
|
+$125K |
| 3 |
MWM
Mascoma Wealth Management
Hanover,
New Hampshire
|
+$26.1K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$349 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sepio Capital
Salt Lake City,
Utah
|
-$744K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$250K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$218K |
| 4 |
Renaissance Technologies
New York
|
-$206K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$95.3K |
MACK Hedge Fund Activity: Q3 2021 in Review
39 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2021, worth a combined $37.3M — down 26% from $50.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of MACK and 2 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 4 added.
The largest buyer was Point72 Asset Management, adding an estimated $689K. The largest seller was Sepio Capital, cutting an estimated $744K.
- 39 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2021, down from 43 in Q2 2021.
- Funds reported $37.3M of Merrimack Pharmaceuticals, Inc. stock for Q3 2021, down 26% quarter-over-quarter.
- 2 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2021 and 6 closed out, a net change of -4 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2021 was Point72 Asset Management, an estimated $689K added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2021 was Sepio Capital, an estimated $744K sold.
Based on aggregated 13F filings for Q3 2021.